Success of HPV vaccination is now a matter of coverage.

摘要

In a pair of articles in The Lancet Oncology, Lehtinen and colleagues and Wheeler and colleagues present 4-year end-of-study data from a trial of a prophylactic human papillomavirus (HPV)-l6/-l8 vaccine (Cervarix, GlaxoSmithKline) in young women aged 15-25 years. From a public-health perspective, these studies have several important contributions.The results assure us that among HPV-naive women in the 15-25 year age range, Cervarix has extremely high efficacy against HPV-l6/-l8-associated persistent infection, CIN2, and CIN3 or worse, the best ethical surrogate endpoint for prospective studies of invasive cervical cancer risk. Combined with other trials of Cervarix and Merck's quadrivalent Gardasil vaccine against HPV-16/-18/-6/-11,3 the evidence is strong for near 100% prophylactic vaccine efficacy in HPV-naive women at any age.